Search Results - "Taleb, Cherifa"

First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers by Landre, Thierry, Des Guetz, Gaetan, Chouahnia, Kader, Taleb, Cherifa, Vergnenègre, Alain, Chouaïd, Christos

“…Aims Single-agent anti-PD-1/PD-L1 clinical efficacy against < 1% PD-L1-expressing non-small-cell lung cancers (NSCLCs) is controversial. Methods This…”
Get full text

Prevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort Study by Martinez-Tapia, Claudia, Rougette, Kevin, Fossey-Diaz, Virginie, Cudennec, Tristan, Taleb, Cherifa, Balardy, Laurent, Mertens, Cécile, Mitha, Nathalie, Bringuier, Michael, Maley, Karin, Estivin, Sandrine, Quipourt, Valérie, Canoui-Poitrine, Florence, Baldini, Capucine, Poisson, Johanne, Paillaud, Elena

“…Older cancer patients have an elevated risk of sarcopenia. The aim was to estimate the prevalence of four criteria for sarcopenia case finding, assessment,…”
Get full text

Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials by Landre, Thierry, Justeau, Gregoire, Assié, Jean-Baptiste, Chouahnia, Kader, Davoine, Claire, Taleb, Chérifa, Chouaïd, Christos, Duchemann, Boris

“…Purpose The most frequent mutation in advanced non-small–cell lung cancer (NSCLC), Kirsten rat-sarcoma viral oncogene ( KRAS ) is found in 20–25% of these…”
Get full text

Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC) by Landre, Thierry, Chouaïd, Christos, Sadaoui, Nassyma, Bouharati, Djamila, Taleb, Chérifa

“…Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC. However, the clinical benefit of this…”
Get full text

Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients by Landre, Thierry, Maillard, Emilie, Taleb, Chérifa, Ghebriou, Djamel, Guetz, Gaetan Des, Zelek, Laurent, Aparicio, Thomas

“…Introduction The clinical benefit of double-front-line therapy (including oxaliplatin or irinotecan or bevacizumab plus 5-fluorouracil (5FU) or capecitabine)…”
Get full text

Efficacy of abemaciclib, palbociclib and ribociclib among the older compared with younger women in HR-positive/HER2-negative, advanced breast cancer by Landre, Thierry, Fain, Anna, Langeron, Emmanuelle, Mokrane, Lakhdar, Taleb, Cherifa

“…Abstract only…”
Get full text

Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 by Landre, Thierry, Des Guetz, Gaetan, Chouahnia, Kader, Taleb, Cherifa, Vergnenegre, Alain, Chouaid, Christos

“…Abstract only 9061 Background: Clinical efficacy of single agent anti-PD-1/PD-L1 in patients with Non-Small-Cell-Lung-Cancer (NSCLC) that were PD-L1 negative…”
Get full text

Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour? by Landre, Thierry, Taleb, Cherifa, Nicolas, Patrick, Des Guetz, Gaetan

“…Abstract only…”
Get full text

Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis by Gendarme, Sébastien, Goussault, Helene, Assié, Jean-Baptiste, Taleb, Cherifa, Chouaïd, Christos, Landre, Thierry

“…Although organized, low-dose, computed-tomography (CT) scan lung-cancer screening has been shown to lower all-cause and lung-cancer-specific mortality, the…”
Get full text

Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis by Landre, Thierry, Uzzan, Bernard, Nicolas, Patrick, Aparicio, Thomas, Zelek, Laurent, Mary, Florence, Taleb, Cherifa, Des Guetz, Gaetan

“…Background The clinical benefit of first-line doublet chemotherapy (including oxaliplatin or irinotecan) compared to single-drug therapy (5FU) in elderly…”
Get full text

Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients by Landre, Thierry, Aparicio, Thomas, Ghebriou, Djamel, Nicolas, Patrick, Taleb, Cherifa, Chouahnia, Kader, Zelek, Laurent H., Des Guetz, Gaetan

“…Abstract only e15034 Background: The clinical benefit of double-front-line therapy (including oxaliplatin or irinotecan or bevacizumab plus 5FU or…”
Get full text

Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis by Landre, Thierry, Guetz, Gaetan Des, Chouahnia, Kader, Fossey-Diaz, Virginie, Taleb, Cherifa, Culine, Stephane

“…Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in…”
Get full text

Checkpoint inhibitors, the perspectives for elderly patients by Landre, Thierry, Karaoud, Fatima, Taleb, Cherifa

“…The arrival of new immunotherapies, called checkpoint inhibitors, is radically changing the world of oncology. Currently, there are some twenty different…”
Get more information

Prevalence of second primary cancers in a geriatric oncology hospital population by Landre, Thierry, El Hadj, Nassima, Taleb, Cherifa, Uzzan, Bernard, Dulou, Lydie, Sebbane, Georges, Des Guetz, Gaetan

“…Abstract only…”
Get full text

Is there a benefit of TKIs among the elderly compared with younger patients in non-small cell lung cancer? a meta-analysis by Landre, Thierry, Nicolas, Patrick, Uzzan, Bernard, Chouahnia, Kader, Taleb, Cherifa, Boudabous, Hanene, Zelek, Laurent H., Des Guetz, Gaetan

“…Abstract only…”
Get full text

Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials by Landre, Thierry, Justeau, Gregoire, Assié, Jean-baptiste, Chouahnia, Kader, Taleb, Chérifa, Chouaid, Christos, Duchemann, Boris

“…Abstract only 9025 Background: KRAS comprise the most frequently found oncogene driver mutation in non-small cell lung cancer (NSCLC), accounting for 20-25% of…”
Get full text

Assessment of nursing needs and risk management in geriatric oncology by Taleb, Cherifa, Landre, Thierry, Bertrand, Eric, Schlatter, Joël, Ratiney, Robert, des Guetz, Gaëtan

“…In France, the incidence and rate of mortality of cancer increase with age. For elderly patients suffering from cancer, the standard geriatric assessment,…”
Get more information

Hypovitaminosis C in hospitalized patients by Fain, Olivier, Pariés, Jacques, Jacquart, Benoı̂t, Le Moël, Giséle, Kettaneh, Adrien, Stirnemann, Jérôme, Héron, Célia, Sitbon, Muriel, Taleb, Chérifa, Letellier, Edouard, Bétari, Bouchra, Gattegno, Liliane, Thomas, Michel

“…Background: In recent years, cases of scurvy have mainly been described in populations at risk. The prevalence and risk factors for hypovitaminosis C among…”
Get full text